全球首款膀胱癌创新疗法获FDA批准上市当地时间6月12日,UroGen Pharma宣布,美国FDA已正式批准其创新疗法UGN-102(Mitomycin)的新药上市申请,用于治疗低级别中危非肌层浸润性膀胱癌(LG-IR-NMIBC)。UroGen Pharma新闻稿指出,这是FDA批准的首款用于治疗LG-IR-NMIBC的药物。UGN-102膀胱灌注溶液是UroGen公司依托其专有RTGel®...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.